文献类型：期刊文献

英文题名：Furmonertinib plus pemetrexed in the treatment of EGFR exon 19 deletion lung adenocarcinoma: two case reports

作者：Zhang, Yuan[1];Wang, Duofang[1];Ma, Huaxiu[1];Wang, Xiaojun[1,2]

第一作者：张媛;张元

通信作者：Wang, XJ[1];Wang, XJ[2]

机构：[1]Gansu Univ Chinese Med, Sch Clin Med 1, Lanzhou, Gansu, Peoples R China;[2]Gansu Prov Hosp, Dept Resp & Crit Care Med, Lanzhou, Gansu, Peoples R China

第一机构：甘肃中医药大学

通信机构：[1]corresponding author), Gansu Univ Chinese Med, Sch Clin Med 1, Lanzhou, Gansu, Peoples R China;[2]corresponding author), Gansu Prov Hosp, Dept Resp & Crit Care Med, Lanzhou, Gansu, Peoples R China.|[10735]甘肃中医药大学;

年份：2026

卷号：16

外文期刊名：FRONTIERS IN ONCOLOGY

收录：;WOS:【SCI-EXPANDED(收录号:WOS:001686969200001)】；

基金：The author(s) declared that financial support was received for this work and/or its publication. The Science-Technology Foundation for Scientist of the Lanzhou City of China (Grant no. 2023-2-54), The Scientists Fund of the Gansu Provincial Hospital of China (Grant no. 23JRRA1758 and 25JRRA1208), The Research Project from Health Commission of Gansu Province of China (Grant no. GSWSQN2024-07), The Scientists Fund of the Gansu Provincial Hospital of China (Grant no. 24GSSYE-3).

语种：英文

外文关键词：EGFR exon 19 deletion; furmonertinib; lung adenocarcinoma; pemetrexed; treatment response

摘要：Epidermal growth factor receptor (EGFR) exon 19 deletion (Ex19del) is one of the most prevalent sensitizing mutations in non-small cell lung cancer (NSCLC), particularly in Asian populations. However, management after progression or suboptimal response is unclear. We describe two patients with advanced lung adenocarcinoma harboring EGFR Ex19del who received furmonertinib plus pemetrexed. Case 1 achieved partial response (PR) with substantial tumor shrinkage and a marked decline in carcinoembryonic antigen (CEA) after six cycles; disease remained stable over 19 months of follow-up. Case 2 had suboptimal benefit from first-line osimertinib but attained PR with resolution of pleural effusion after switching to the combination; subsequent computed tomography (CT) confirmed stable disease (SD). Both patients tolerated treatment without severe treatment-related adverse events. These observations suggest that furmonertinib plus pemetrexed may have antitumor activity and acceptable tolerability in EGFR Ex19del lung adenocarcinoma, and may inform personalized approaches following resistance to first-line therapy in EGFR-sensitizing NSCLC.